Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer

This publication has 15 references indexed in Scilit:

• New prognostic indicator for non‐small‐cell lung cancer, quantitation of thymidylate synthase by real‐time reverse transcription polymerase chain reaction
  International Journal of Cancer, 2003
• Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer
  Journal of Surgical Oncology, 2002
• Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil
  Lung Cancer, 2001
• Relationship between Protein Levels and Gene Expression of Dihydropyrimidine Dehydrogenase in Human Tumor Cells during Growth in Culture and in Nude Mice
  Japanese Journal of Cancer Research, 1998
• Advantage of post-operative oral administration of UFT (Tegafur and Uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC)1
  European Journal of Cardio-Thoracic Surgery, 1998
• A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance
  Cancer, 1998
• Revisions in the International System for Staging Lung Cancer
  Chest, 1997
• Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
  Journal of Clinical Oncology, 1996
• A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil
  European Journal Of Cancer, 1994
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958